What is the 13F Pro Quality Score for KALA?

13F Pro ranks KALA BIO, Inc. (KALA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KALA's current score at https://13fpro.ai/company/KALA (free sign-up required for the full ranking).

Where does 13F Pro source KALA data?

All KALA BIO, Inc. fundamentals and ownership data come directly from SEC EDGAR. KALA BIO, Inc. files with the SEC under CIK 1479419. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KALA in?

KALA BIO, Inc. (KALA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KALA research updated on 13F Pro?

KALA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

KALA BIO, Inc.(KALA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1479419 KALA stock profile & AI dashboard →

13F Pro Quality Score

26.3/100

Rank #2,583 of 2,884 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

30.0/100

Profitability

30.0/100

Balance Sheet

1.1/100

Earnings Quality

8.1/100

Free Cash Flow

30.0/100

Institutional Flow

58.1/100

Revenue Scale

30.0/100

Dilution Risk

30.0/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why KALA Scores 26/100

exact factor attribution · 2026-08-18

KALA's composite is held back by capital efficiency and earnings quality. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+0.4 pts

58th pct

Earnings growth

-1.0 pts

30th pct

Shareholder dilution

-1.0 pts

30th pct

Free cash flow

-3.0 pts

30th pct

Profitability

-3.0 pts

30th pct

Scale

-3.0 pts

30th pct

Revenue growth

-4.0 pts

30th pct

Earnings quality

-4.2 pts

8th pct

Capital efficiency

-4.9 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

KALA Stock Analysis & AI Quality Score

Data updated 2026-08-18

AI stock analysis and institutional research for KALA BIO, Inc. (KALA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores KALA at 26.3/100 on a 32-signal composite quality model, placing it at rank #2,583 of 2,884 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.1) and earnings quality (8.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.0/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of KALA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. KALA trades on the Nasdaq exchange and files with the SEC under CIK 1479419. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KALA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for KALA BIO, Inc. directly from SEC EDGAR.

Net Income

Q2 2026

$-1.6M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

$0.00FY 2025

FY22 $3.9MFY23 $0.00FY24 $0.00FY25 $0.00

Net Income

+29.9% YoY

$-27.0MFY 2025

FY22 $-44.8MFY23 $-42.2MFY24 $-38.5MFY25 $-27.0M

Operating Income

+4.4% YoY

$-39.2MFY 2025

FY22 $-81.7MFY23 $-39.7MFY24 $-41.0MFY25 $-39.2M

EPS (Diluted)

+67.4% YoY

$-3.31FY 2025

FY22 $-29.48FY23 $-17.35FY24 $-10.15FY25 $-3.31

Total Assets

-82.9% YoY

$9.5MFY 2025

FY22 $86.8MFY23 $55.9MFY24 $55.5MFY25 $9.5M

Total Debt

—FY 2025

FY22 $48.3MFY23 $34.2MFY24 $39.6MFY25 —

Op. Cash Flow

-8.9% YoY

$-32.0MFY 2025

FY22 $-78.9MFY23 $-27.9MFY24 $-29.4MFY25 $-32.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00	$0.00	$0.00 -100.0%	$3.9M -65.4%	$11.2M +76.7%	$6.4M
Net Income	$-27.0M +29.9%	$-38.5M +8.7%	$-42.2M +5.9%	$-44.8M +68.6%	$-142.6M -36.7%	$-104.3M
Operating Income	$-39.2M +4.4%	$-41.0M -3.3%	$-39.7M +51.5%	$-81.7M +37.3%	$-130.2M -35.3%	$-96.2M
EPS (Diluted)	$-3.31 +67.4%	$-10.15 +41.5%	$-17.35 +41.1%	$-29.48 +70.1%	$-98.47 -5343.2%	$-1.81
Total Assets	$9.5M -82.9%	$55.5M -0.8%	$55.9M -35.6%	$86.8M -37.7%	$139.4M -37.1%	$221.6M
Total Debt	—	$39.6M +15.9%	$34.2M -29.2%	$48.3M -39.6%	$80.0M +6.7%	$75.0M
Operating Cash Flow	$-32.0M -8.9%	$-29.4M -5.2%	$-27.9M +64.6%	$-78.9M +27.1%	$-108.2M -19.3%	$-90.7M

Get alerted when KALA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for KALA BIO, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KALA

VANGUARD CAPITAL MANAGEMENT LLC
$381.7K220,623 sh
GEODE CAPITAL MANAGEMENT, LLC
$251.1K145,152 sh
VANGUARD FIDUCIARY TRUST CO
$175.4K101,396 sh
BlackRock, Inc.
$123.8K71,542 sh
NORTHERN TRUST CORP
$72.0K41,606 sh
Qube Research & Technologies Ltd
$19.2K11,073 sh
GOLDMAN SACHS GROUP INC
$18.9K10,921 sh
UBS Group AG
$15.7K9,057 sh
Tower Research Capital LLC (TRC)
$1.1K616 sh
BARCLAYS PLC
$1.1K608 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$381.7K	220,623
GEODE CAPITAL MANAGEMENT, LLC	$251.1K	145,152
VANGUARD FIDUCIARY TRUST CO	$175.4K	101,396
BlackRock, Inc.	$123.8K	71,542
NORTHERN TRUST CORP	$72.0K	41,606
Qube Research & Technologies Ltd	$19.2K	11,073
GOLDMAN SACHS GROUP INC	$18.9K	10,921
UBS Group AG	$15.7K	9,057
Tower Research Capital LLC (TRC)	$1.1K	616
BARCLAYS PLC	$1.1K	608

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KALA on your watchlist

Track score changes the day KALA BIO, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KALA a good stock to buy?

13F Pro's AI-powered analysis of KALA BIO, Inc. (KALA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KALA are available on the KALA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. KALA is classified as a small company.

Which hedge funds own KALA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KALA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of KALA BIO, Inc.'s investment landscape.